Methicillin-resistant Staphylococcus aureus: the superbug

Int J Infect Dis. 2010 Oct;14 Suppl 4:S7-11. doi: 10.1016/j.ijid.2010.05.003. Epub 2010 Sep 20.

Abstract

Over the last decade, methicillin-resistant Staphylococcus aureus (MRSA) strains have emerged as serious pathogens in the nosocomial and community setting. Hospitalization costs associated with MRSA infections are substantially greater than those associated with methicillin-sensitive S. aureus (MSSA) infections, and MRSA has wider economic effects that involve indirect costs to the patient and to society. In addition, there is some evidence suggesting that MRSA infections increase morbidity and the risk of mortality. Glycopeptides are the backbone antibiotics for the treatment of MRSA infections. However, several recent reports have highlighted the limitations of vancomycin, and its role in the management of serious infections is now being reconsidered. Several new antimicrobials demonstrate in vitro activity against MRSA and other Gram-positive bacteria. Data from large surveys indicate that linezolid, daptomycin, and tigecycline are almost universally active against MRSA. This review will briefly discuss the epidemiology, costs, outcome, and therapeutic options for the management of MRSA infections.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Acetamides / pharmacology
  • Acetamides / therapeutic use
  • Anti-Bacterial Agents / pharmacology
  • Anti-Bacterial Agents / therapeutic use*
  • Bacteremia / drug therapy
  • Bacteremia / economics
  • Bacteremia / epidemiology
  • Bacteremia / microbiology
  • Cross Infection* / drug therapy
  • Cross Infection* / economics
  • Cross Infection* / epidemiology
  • Cross Infection* / microbiology
  • Daptomycin / pharmacology
  • Daptomycin / therapeutic use
  • Humans
  • Linezolid
  • Methicillin-Resistant Staphylococcus aureus / drug effects*
  • Methicillin-Resistant Staphylococcus aureus / pathogenicity
  • Minocycline / analogs & derivatives
  • Minocycline / pharmacology
  • Minocycline / therapeutic use
  • Oxazolidinones / pharmacology
  • Oxazolidinones / therapeutic use
  • Staphylococcal Infections* / drug therapy
  • Staphylococcal Infections* / economics
  • Staphylococcal Infections* / epidemiology
  • Tigecycline
  • Treatment Outcome

Substances

  • Acetamides
  • Anti-Bacterial Agents
  • Oxazolidinones
  • Tigecycline
  • Minocycline
  • Linezolid
  • Daptomycin